INSP Quote, Financials, Valuation and Earnings

Myomo has a net margin of 9.1% compared to Inspire Medical Systems's net margin of -10.5%. Inspire Medical Systems's return on equity of 5.44% beat Myomo's return on equity of -84.04%.

Inspire Medical Systems has a consensus price target of $239.60, signalling upside risk potential of 28.62%. On the other hand Myomo has an analysts' consensus of $7.04 which suggests that it could grow by 19.42%. Given that Inspire Medical Systems has higher upside potential than Myomo, analysts believe Inspire Medical Systems is more attractive than Myomo.

Inspire Medical Systems has a beta of 1.313, which suggesting that the stock is 31.289% more volatile than S&P 500. In comparison Myomo has a beta of 1.709, suggesting its more volatile than the S&P 500 by 70.858%.

Inspire Medical Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inspire Medical Systems pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Inspire Medical Systems quarterly revenues are $203.2M, which are larger than Myomo quarterly revenues of $9.2M. Inspire Medical Systems's net income of $18.5M is higher than Myomo's net income of -$966.4K. Notably, Inspire Medical Systems's price-to-earnings ratio is 174.10x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inspire Medical Systems is 7.41x versus 9.38x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Inari Medical has a net margin of 9.1% compared to Inspire Medical Systems's net margin of -11.97%. Inspire Medical Systems's return on equity of 5.44% beat Inari Medical's return on equity of -17.68%.

Inspire Medical Systems has a consensus price target of $239.60, signalling upside risk potential of 28.62%. On the other hand Inari Medical has an analysts' consensus of $66.46 which suggests that it could grow by 23.88%. Given that Inspire Medical Systems has higher upside potential than Inari Medical, analysts believe Inspire Medical Systems is more attractive than Inari Medical.

Inspire Medical Systems has a beta of 1.313, which suggesting that the stock is 31.289% more volatile than S&P 500. In comparison Inari Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Inspire Medical Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inari Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inspire Medical Systems pays -- of its earnings as a dividend. Inari Medical pays out -- of its earnings as a dividend.

Inspire Medical Systems quarterly revenues are $203.2M, which are larger than Inari Medical quarterly revenues of $153.4M. Inspire Medical Systems's net income of $18.5M is higher than Inari Medical's net income of -$18.4M. Notably, Inspire Medical Systems's price-to-earnings ratio is 174.10x while Inari Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inspire Medical Systems is 7.41x versus 5.42x for Inari Medical. Usually stocks with elevated PS ratios are considered overvalued.

Nevro has a net margin of 9.1% compared to Inspire Medical Systems's net margin of -15.83%. Inspire Medical Systems's return on equity of 5.44% beat Nevro's return on equity of -24.66%.

Inspire Medical Systems has a consensus price target of $239.60, signalling upside risk potential of 28.62%. On the other hand Nevro has an analysts' consensus of $5.68 which suggests that it could grow by 43.16%. Given that Nevro has higher upside potential than Inspire Medical Systems, analysts believe Nevro is more attractive than Inspire Medical Systems.

Inspire Medical Systems has a beta of 1.313, which suggesting that the stock is 31.289% more volatile than S&P 500. In comparison Nevro has a beta of 0.841, suggesting its less volatile than the S&P 500 by 15.88%.

Inspire Medical Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nevro offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inspire Medical Systems pays -- of its earnings as a dividend. Nevro pays out -- of its earnings as a dividend.

Inspire Medical Systems quarterly revenues are $203.2M, which are larger than Nevro quarterly revenues of $96.9M. Inspire Medical Systems's net income of $18.5M is higher than Nevro's net income of -$15.3M. Notably, Inspire Medical Systems's price-to-earnings ratio is 174.10x while Nevro's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inspire Medical Systems is 7.41x versus 0.35x for Nevro. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of 9.1% compared to Inspire Medical Systems's net margin of -67.31%. Inspire Medical Systems's return on equity of 5.44% beat Stereotaxis's return on equity of -108.68%.

Inspire Medical Systems has a consensus price target of $239.60, signalling upside risk potential of 28.62%. On the other hand Stereotaxis has an analysts' consensus of -- which suggests that it could grow by 92.31%. Given that Stereotaxis has higher upside potential than Inspire Medical Systems, analysts believe Stereotaxis is more attractive than Inspire Medical Systems.

Inspire Medical Systems has a beta of 1.313, which suggesting that the stock is 31.289% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.570, suggesting its more volatile than the S&P 500 by 57.046%.

Inspire Medical Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inspire Medical Systems pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Inspire Medical Systems quarterly revenues are $203.2M, which are larger than Stereotaxis quarterly revenues of $9.2M. Inspire Medical Systems's net income of $18.5M is higher than Stereotaxis's net income of -$6.2M. Notably, Inspire Medical Systems's price-to-earnings ratio is 174.10x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inspire Medical Systems is 7.41x versus 7.83x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.